Hereditary Hemochromatosis SNPs: What Dysautonomia Patients Need to Know

Hereditary hemochromatosis (HH) is one of the most common genetic disorders in populations of Northern European descent, affecting approximately 1 in 200–300 individuals of this background. It is caused by variants in the HFE gene that impair the body's ability to regulate iron absorption, leading to progressive iron accumulation in organs including the liver, heart, pancreas, and nervous system. For dysautonomia patients, iron overload has direct relevance — iron deposits in the autonomic ganglia, heart, and endocrine organs can directly worsen or cause autonomic dysfunction.

The HFE Gene and Key Variants

The HFE gene encodes a protein that regulates hepcidin — the master hormone controlling iron absorption in the gut. Two HFE variants account for the vast majority of hereditary hemochromatosis cases:

C282Y homozygosity (two copies of the C282Y variant) is the classic hemochromatosis genotype and carries the highest risk of iron overload. However, penetrance is incomplete — approximately 30–50% of C282Y homozygotes develop clinically significant iron overload, and only 10–20% develop end-organ damage without treatment.

C282Y/H63D compound heterozygosity (one copy of each) carries intermediate risk — most compound heterozygotes do not develop significant iron overload, but a subset does, particularly in the presence of other risk factors (alcohol use, metabolic syndrome, steatohepatitis).

H63D homozygosity is generally considered low risk for significant iron overload but may contribute to mildly elevated ferritin levels, particularly in the presence of other metabolic stressors.

Iron Overload and Autonomic Dysfunction

The connection between iron overload and autonomic dysfunction is direct and well-documented:

Cardiac autonomic neuropathy. Iron deposits in the myocardium and cardiac conduction system can cause arrhythmias, heart failure, and autonomic neuropathy. Cardiac hemochromatosis is a leading cause of death in untreated hereditary hemochromatosis.

Autonomic ganglia deposits. Iron can accumulate in the sympathetic and parasympathetic ganglia, directly impairing autonomic nerve function. This has been documented in post-mortem studies of hemochromatosis patients and may contribute to orthostatic intolerance.

Endocrine disruption. Iron deposits in the pancreas (causing diabetes), pituitary gland (causing hypogonadism), and adrenal glands can disrupt the hormonal regulation of autonomic function.

Oxidative stress. Excess iron catalyzes the Fenton reaction, generating highly reactive hydroxyl radicals that damage cellular membranes, mitochondria, and DNA. Oxidative stress in autonomic neurons and ganglia may contribute to autonomic dysfunction even before frank iron overload develops.

Ferritin as a Screening Tool

For dysautonomia patients with HFE variants, serum ferritin and transferrin saturation are the primary screening tests for iron overload. However, ferritin is an acute-phase reactant — it can be elevated by inflammation, infection, liver disease, and metabolic syndrome independent of iron overload. Transferrin saturation above 45% (women) or 50% (men) is a more specific indicator of iron overload.

If ferritin is persistently elevated (above 200 ng/mL in women or 300 ng/mL in men) with elevated transferrin saturation, referral to a hematologist or hepatologist for further evaluation (including liver biopsy or MRI for iron quantification) is warranted.

Treatment: Therapeutic Phlebotomy

The treatment for hereditary hemochromatosis is straightforward and highly effective: therapeutic phlebotomy (regular blood removal). Each unit of blood (450–500 mL) removes approximately 200–250 mg of iron. The goal is to reduce ferritin to 50–100 ng/mL and maintain it in this range.

For C282Y homozygotes with iron overload, weekly phlebotomy is typically initiated until iron stores are depleted, followed by maintenance phlebotomy every 2–4 months. For patients who cannot tolerate phlebotomy (severe anemia, cardiovascular instability), iron chelation therapy (deferasirox, deferoxamine) is an alternative.

Importantly, therapeutic phlebotomy has been shown to improve cardiac function, reduce liver fibrosis, and improve quality of life in hemochromatosis patients. For dysautonomia patients with iron overload, addressing the iron burden may meaningfully improve autonomic symptoms.

Dietary Considerations

For patients with HFE variants who do not yet have significant iron overload, dietary modifications can reduce iron absorption:

• Avoid cooking in cast iron cookware (particularly for acidic foods)
• Avoid vitamin C supplements with iron-rich meals (vitamin C enhances non-heme iron absorption)
• Tea and coffee with meals reduce iron absorption (tannins inhibit iron uptake)
• Avoid iron-fortified foods and supplements unless anemia is documented
• Alcohol significantly increases iron absorption and should be minimized

Key Takeaways

HFE variants are among the most common clinically significant genetic findings in the dysautonomia community, and iron overload has direct mechanistic relevance to autonomic dysfunction. For dysautonomia patients with C282Y or H63D variants, regular monitoring of ferritin and transferrin saturation is warranted. If iron overload is identified, therapeutic phlebotomy is safe, effective, and may improve autonomic symptoms. This is one of the most actionable genetic findings for dysautonomia patients.

This article is for informational purposes only and does not constitute medical advice.